Suarez-Zdunek, Moises Alberto
Saini, Sunil Kumar
Pedersen, Christian Ross
Hamm, Sebastian Rask
Hald, Annemette
Rasmussen, Allan
Hillingsø, Jens Georg
Hadrup, Sine Reker
Nielsen, Susanne Dam
Funding for this research was provided by:
Novo Nordisk Fonden (0073947)
Article History
Received: 7 February 2023
Accepted: 13 March 2023
First Online: 6 April 2023
Declarations
:
: The immunological substudy has been approved by the Ethics Committee of the Capital Region of Denmark (H-22039226) and the Knowledge Centre for Data Reviews of the Capital Region of Denmark (P-2022-952), and participants provide oral and written consent. As data for the epidemiological substudy are collected from hospital records, the substudy is exempt from provision of informed consent in accordance with Danish law and has been approved by the Centre for Regional Development of the Capital Region of Denmark (R-20051155) and the Knowledge Centre for Data Reviews of the Capital Region of Denmark (P-2020-839).
: Not applicable.
: S.R. Hadrup is the inventor of the antigen scaffold technology, E Patent Appl No. 16205918.2 and 18178769.8, license to PokeACell (S.R. Hadrup as co-founder). S.D.N. has received unrestricted research grants from Novo Nordisk Foundation, Lundbeck Foundation, Augustinus Foundation, and Rigshospitalet Research Council, and reports advisory board activity for Gilead Sciences and GlaxoSmithKline/ViiV Healthcare, all unrelated to this manuscript. The other authors report no competing interests.